he
"CoffeeMeter"
will utilize existing blood glucose reagent strips (from
most current manufacturers). Through a new method of optical processing,
it will be able to measure caffeine consumption,
which will be displayed on the
meter in "CCE"
(Coffee Cup Equivalent) units.
The
"CoffeeMeter"
has been tested
in several clinical settings,
including diabetes clinics, inpatient
alcohol treatment units, and wellness programs. It has had
great success (P<0.05%) in
predicting the likelihood of coffee withdrawal symptoms
as caffeine levels decline.
The
"CoffeeMeter"
can also accurately discriminate whether the user
had consumed caffeinated or "decaf"
coffee.
More details on this very
important new product should be forthcoming in the near future.
